Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL
- Status
- UNKNOWN
- Phase
- PHASE3
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
- Status
- UNKNOWN
- Phase
- PHASE1
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE3
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Treatment of Sickle Cell Anemia With Stem Cell Transplant
- Status
- TERMINATED
- Phase
- NA
Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation
- Status
- TERMINATED
- Phase
- PHASE2
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
- Status
- COMPLETED
- Phase
- PHASE2
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
- Status
- UNKNOWN
- Phase
- PHASE2